Status:
UNKNOWN
Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Korea Research Institute of Bioscience & Biotechnology
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
16-75 years
Brief Summary
The purpose of this study is to evaluate the effect of various clinical variables including HLA-disparity and NK cell-related variables, upon outcomes of allogeneic hematopoietic cell transplantation ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with non-promyelocytic AML (intermediate-risk or high-risk diseases by NCCN guideline 2016) in the first CR
- Patients should be 16 years of age or more and 75 years of age or less
- The performance status of the patients should be 70 or over by Karnofsky performance scale
- Patients should have adequate hepatic function (bilirubin less than 2.0 mg/dl, AST less than three times the upper normal limit)
- Patients should have adequate renal function (creatinine less than 2.0 mg/dl)
- Patients should have adequate cardiac function (ejection fraction \> 40% on MUGA scan)
- Patients and stem cell donors must sign informed consent
- For hematopoietic cell donor, if a patient has an HLA-matched sibling (65 years or younger), that sibling will be a cell donor. If a patient does not have an HLA-matched sibling but an HLA-A, B, C, DRB1 7-8/8 matched unrelated donor, the unrelated donor will be a cell donor. If a patient has neither HLA-matched sibling nor unrelated donor, an HLA-haploidentical familial donor will be a cell donor.
Exclusion
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2021
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT03337568
Start Date
April 1 2017
End Date
March 30 2021
Last Update
July 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea